BridgeBio Pharma Inc

NASDAQ: BBIO
$26.83
+$0.87 (+3.4%)
Closing Price on September 19, 2024

BBIO Chart and Intraday Price

BBIO Company Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 421 KIPLING STREET, PALO ALTO, CA, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 6,264.89M USD
Shares Outstanding 175,832,000
BridgeBio Pharma Inc is a pioneering biopharmaceutical company focused on developing innovative medicines for genetic diseases and cancers. With a robust pipeline, it is advancing treatments through clinical trials, including therapies for TTR amyloidosis, achondroplasia, congenital adrenal hyperplasia, autosomal dominant hypocalcemia, and limb-girdle muscular dystrophy. Founded in 2015 and based in Palo Alto, California, BridgeBio collaborates with leading institutions to transform scientific discoveries into breakthrough treatments.

BBIO Articles

Wednesday's Top Analyst Upgrades and Downgrades: Chesapeake Energy, eBay, Hewlett Packard Enterprise, Oracle, Phillips 66, US Steel and More
Wednesday's top analyst upgrades and downgrades included Accenture, Bridgebio Pharma, Chesapeake Energy, eBay, Hewlett Packard Enterprise, Huntsman, New York Community Bancorp, Nucor, Oracle, PBF...
Lee Jackson
Published:

Wednesday's Top Analyst Upgrades and Downgrades: Adobe, Ciena, Hilton, Paysafe, Riot Blockchain, Shopify, Tesla and More
Wednesday’s top analyst upgrades and downgrades included Adobe, Akamai Technologies, BridgeBio Pharma, Ciena, Eqonex, Hilton Worldwide, Paysafe, Riot Blockchain, Shopify, Tesla and Williams-Sonoma.
Lee Jackson
Published: